Navigation Links
Hard To Treat Diseases (HTDS) Best Technological Innovation Award 2009
Date:3/31/2009

BELGRADE, SERBIA, March 31 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS) www.htdsmedical.com - The "Best Technological Innovation Award" is a most coveted, prestigious award, and is announced annually by the Serbian Ministry of Science and Technological Development. Submitted with the award application, HTDS included extremely encouraging results from the preliminary trial of their Ribavirin product, confirming its combative effective against glial scarring.

HTDS Chief Scientist, Dr. Sanja Pekovic was elected as an expert to represent Serbia in the COST (European Cooperation In The Field of Scientific And Technical Research) Action B30: Neural Regeneration and Plasticity. Meetings are scheduled twice a year.

Recently, HTDS - IBISS GROUP competed for the European Collaborative Project (FP7). Dr. Pekovic said "We are delighted to have successfully passed the first level of selection. HTDS is looking forward to another great year." Final results will be released sometime in 2009.

The company will provide further details as they become available.

Safe Harbor

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Australian clinical trials threatened: Jobs and patient access to new treatments at stake
2. US Market for Minimally Invasive Treatment of Varicose Veins to Rise to More than $215 Million by 2013
3. Prostate Cancer Patients in US and Europe Receive Treatments Using Enhanced Seed Prostate Brachytherapy Software
4. Ear Health News: Natural Treatments to Ease Tinnitus Intensity
5. Arthritis Treatments and Joint Pain Relief Ideas Featured on Newly Launched Arthritis Today Web Site
6. New Device Treats Common Heart Rhythm Disorder
7. Hard to Treat Diseases (HTDS) clinical trial protocol for MMR Vaccine expected Q2 2009
8. Microsurgery May Cut Swelling After Breast Cancer Treatment
9. Treatment Target for Herpes Pinpointed
10. Plastic Surgeon Allan Parungao, MD, FACS, Announces Clinical Trial of Juvderm Technique to Treat Root Cause of Midface Sagging, without Surgery
11. Individualized stroke treatment available for patients, though underutilized
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... ... enterprise Data Center Infrastructure Management solutions, announces today the availability of its ... in the area of capacity management and optimization, providing new analytical capabilities ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... in Aesthetic Surgery Education and Anzu®, developers of the AnzuMedical™ Knowledge Sharing ... Plastic Surgery Collaborative Residency Network. The platform is scheduled to launch in July ...
(Date:4/28/2016)... Cary, NC (PRWEB) , ... April 28, 2016 ... ... to announce it has partnered with Community Oncology Pharmacy Association (COPA) to develop ... elevate the practice of oncology by introducing an accreditation distinction. ACHC provides a ...
(Date:4/28/2016)... ... ... The Aging in Motion Coalition (AIM) has announced the Centers ... it recognition for separate reporting and data collection. The code, M62.84, will be available ... as a combination of low muscle mass and weakness in older adults that causes ...
(Date:4/28/2016)... ... 28, 2016 , ... The USDA recently released its updated Dietary Guidelines for ... While there is a lot of information available in the report, older men should ... issue of Harvard Men's Health Watch . , These include: , 1.    Vary ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 Research ... "Global Plastic Surgery Products Market 2016-2020" report to ... ) , The global plastic surgery products ... 9.47% during the period 2016-2020. , ,The growing adoption ... to the growth of the market. Lasers are used ...
(Date:4/28/2016)... , Net Sales of $1.90 billion represent ... prior year period, and an increase of 1.2% on an ... for the first quarter were $0.52 reported, a decrease of ... increase of 29.9% over the prior year period , ... for 2016 Zimmer Biomet Holdings, Inc. (NYSE and ...
(Date:4/28/2016)... , April 28, 2016 ... development of innovative peptide and gene-based immunotherapeutics and vaccines for ... will be presenting at the 3rd Annual Growth Capital ... 5 th , 2016 at Caesars Palace in Las Vegas, Nevada.  ... am on Wednesday, May 4 th by Dr. ...
Breaking Medicine Technology: